Waki K, Sugawara Y, Mizuta K, Fujita H, Kadowaki T, Kokudo N
Department of Ubiquitous Health Informatics, Graduate School of Medicine, University of Tokyo, Tokyo, Japan.
Clin Transpl. 2011:223-35.
We analyzed a single center's experience during 16 years of living-donor liver transplantation (LDLT). The impacts of HLA mismatches and positive crossmatches on long term outcomes and tolerance were evaluated.
This study was of primary LDLTs of consecutive patients from January 1996 to December 2011; re-transplants were not included. Long-term survival was compared by primary disease, number of HLA mismatches, and crossmatches. Demographics and complications after transplantation between pediatric recipients who achieved clinical operational tolerance and those who did not were compared.
One-year liver graft survival rates for adult and pediatric cases were 90.4% and 91.9%, respectively; the 5-year rates were 83.1% and 89.2%, respectively; the 10-year rates were 79.7% and 89.2%, respectively; and 15-year rates were 65.9% and 83.8%, respectively. For the grafts that survived more than one year, the 10-year rates for adult and pediatric cases were 88.2% and 97.0%, respectively. The 10-year rates for adult LDLT in 0 mismatches, 1-2 mismatches, 3-4 mismatches, and 5-6 mismatches were 79.2%, 86.8%, 77.4%, and 69.4%, respectively. Although the survival rates were not significantly different, the survival rates were lowest in LDLT recipients with 5-6 HLA mismatches. Ten-year liver graft survival rates for adult LDLT with negative T-cell crossmatch, and positive T-cell crossmatch were 80.0% and 71.1%, respectively. The 1-year liver graft survival rates for adult LDLT with negative B-cell crossmatch, and positive B-cell crossmatch were 90.6% and 88.2%, respectively. None of the factors--age of recipients and donors, primary disease, donor gender, relationship of donors to recipients, positive crossmatches, or number of HLA mismatches--was significantly different between COT and non-COT recipients, except for recipient gender (p = 0.01); in COT cases, there were more female recipients (88.9%) than male (11.1%). Post-transplant complications--acute rejection rate in one year post-transplant, biliary complications rate, and vascular complication rate--were not significantly different between COT and non-COT recipients.
High long-term survival was achieved by both adult and pediatric recipients. Even higher survival can be achieved by improving early graft loss. Further studies are necessary to determine the impact of HLA mismatches and positive crossmatches on long-term outcomes and tolerance.
我们分析了一个单中心16年活体肝移植(LDLT)的经验。评估了HLA错配和阳性交叉配型对长期预后和免疫耐受的影响。
本研究纳入了1996年1月至2011年12月连续患者的初次LDLT;不包括再次移植。通过原发疾病、HLA错配数量和交叉配型比较长期生存率。比较达到临床手术免疫耐受的小儿受者和未达到的小儿受者移植后的人口统计学和并发症情况。
成人和小儿病例的1年肝移植生存率分别为90.4%和91.9%;5年生存率分别为83.1%和89.2%;10年生存率分别为79.7%和89.2%;15年生存率分别为65.9%和83.8%。对于存活超过1年的移植肝,成人和小儿病例的10年生存率分别为88.2%和97.0%。成人LDLT中0个错配、1 - 2个错配、3 - 4个错配和5 - 6个错配的10年生存率分别为79.2%、86.8%、77.4%和69.4%。虽然生存率无显著差异,但HLA错配为5 - 6个的LDLT受者生存率最低。成人LDLT中T细胞交叉配型阴性和阳性的10年肝移植生存率分别为80.0%和71.1%。成人LDLT中B细胞交叉配型阴性和阳性的1年肝移植生存率分别为90.6%和88.2%。除受者性别外(p = 0.01),COT和非COT受者在受者和供者年龄、原发疾病、供者性别、供者与受者关系、阳性交叉配型或HLA错配数量等因素上均无显著差异;在COT病例中,女性受者(88.9%)多于男性(11.1%)。移植后并发症——移植后1年急性排斥反应率、胆道并发症率和血管并发症率——在COT和非COT受者之间无显著差异。
成人和小儿受者均实现了较高的长期生存率。通过改善早期移植肝丢失可实现更高的生存率。有必要进一步研究以确定HLA错配和阳性交叉配型对长期预后和免疫耐受的影响。